Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fish and Richardson
Express Scripts
Healthtrust
Deloitte
Argus Health
Queensland Health
Boehringer Ingelheim
McKesson

Generated: October 19, 2018

DrugPatentWatch Database Preview

Amarin Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for AMARIN PHARMS, and when can generic versions of AMARIN PHARMS drugs launch?

AMARIN PHARMS has two approved drugs.

There are twenty-five US patents protecting AMARIN PHARMS drugs.

Summary for Amarin Pharms
US Patents:25
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Amarin Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 RX Yes Yes 8,546,372 ➤ Sign Up ➤ Sign Up
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 RX Yes No 8,501,225 ➤ Sign Up ➤ Sign Up
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 RX Yes Yes 8,563,608 ➤ Sign Up ➤ Sign Up
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 RX Yes No 8,617,593 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for AMARIN PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 1 g ➤ Subscribe 2013-01-15
➤ Subscribe Capsules 500 mg ➤ Subscribe 2017-08-29
➤ Subscribe Capsules 1 g ➤ Subscribe 2016-07-26

Supplementary Protection Certificates for Amarin Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009 Belgium ➤ Sign Up PRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION:
C0037 Belgium ➤ Sign Up PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
Healthtrust
Fuji
Johnson and Johnson
Teva
Express Scripts
Cipla
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.